Nebivolol Krka

Nebivolol, the active ingredient in Nebivolol Krka, is a beta blocker presented as an oral tablet for oral use. It treats hypertension and heart failure in adult patients by selectively blocking β1‑adrenergic receptors and enhancing nitric‑oxide mediated vasodilation, which lowers blood pressure and reduces cardiac workload.

GNH USA supplies Nebivolol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Nebivolol is used to manage cardiovascular conditions by lowering blood pressure and improving cardiac function.

Hypertension: Reduces systolic and diastolic blood pressure, helping achieve target levels in patients with essential hypertension. Heart failure: Improves left ventricular ejection fraction and reduces symptoms in patients with chronic heart failure with reduced ejection fraction. Cardiovascular risk reduction: Contributes to endothelial function improvement, potentially lowering overall cardiovascular risk in hypertensive patients.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: Mild to moderate headache reported during early therapy. - Dizziness: Transient light‑headedness, especially after standing. - Fatigue: Generalized tiredness or reduced energy levels. - Bradycardia: Heart rate slower than normal, often asymptomatic. - Nausea: Stomach upset or queasiness. - Insomnia: Difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe bradycardia: Markedly low heart rate requiring medical attention. - Hypotension: Significant drop in blood pressure causing faintness or shock. - Heart block: Atrioventricular conduction disturbances. - Bronchospasm: Worsening of asthma or COPD symptoms. - Allergic reactions: Rash, itching, swelling, or anaphylaxis. - Hepatic injury: Elevated liver enzymes or jaundice.

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure safe use.

Blood pressure monitoring: Check baseline and periodic blood pressure to avoid excessive hypotension. Cardiac function assessment: Evaluate heart rate and ECG, especially in patients with bradycardia. Asthma or COPD caution: Use with care as β‑blockade may precipitate bronchospasm. Concomitant beta‑blocker use: Avoid combining with other β‑blockers to prevent additive effects. Renal/hepatic impairment: Adjust dose or monitor closely in patients with significant organ dysfunction. Store at room temperature: Keep in original packaging, protect from moisture and light.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other beta‑blockers: Additive β‑blockade may cause severe bradycardia or hypotension. - Calcium channel blockers (verapamil, diltiazem): May increase plasma levels of nebivolol. - Clonidine withdrawal: Abrupt discontinuation of clonidine can lead to rebound hypertension. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): Can raise nebivolol concentrations.

Moderate Interactions (Monitor Closely):\n- Non‑dihydropyridine CCBs (e.g., amlodipine): May enhance antihypertensive effect. - Diuretics: Combined effect on blood pressure may require dose adjustment. - NSAIDs: May blunt antihypertensive response, necessitating closer monitoring.